API
< Back to situations

Monitor this situation.

[SITUATION] · [QUIET] · [HEALTH]

2 clusters · 2 sources · 14 days · First seen · Last updated

mRNA technology advancements in cancer treatment

Overview

Recent developments in mRNA technology have shown significant promise in cancer treatment and vaccine efficacy. In a phase 3 clinical trial named INTerpath-001, a personalized mRNA vaccine called intismeran, developed by Merck and Moderna, reduced the risk of melanoma recurrence or death by 42% compared to immunotherapy alone. The study involved 1,137 patients and found that 82% of those receiving the combination therapy were alive without the cancer returning after two years.

Further research at Johns Hopkins Medicine has identified a method to potentially increase the efficiency of mRNA-based treatments by allowing cells to read instructions nearly twice as fast. This could lead to higher protein production and more effective treatments using smaller doses. Additionally, Moderna is conducting phase one clinical trials for an experimental vaccine, mRNA-4194, in collaboration with the University of Oxford to evaluate its ability to prevent cancer in individuals with Lynch syndrome.

Entities

Moderna · University of Oxford · Melanoma Institute Australia · Mercury · Uranus

Timeline

  1. [HEALTH] 2 sources
    mRNA technology advancements offer potential for improved vaccine efficacy

    Scientists have found ways to enhance mRNA efficiency, potentially allowing for smaller vaccine doses, while Moderna tests an experimental mRNA vaccine to prevent cancer in high-risk genetic groups.

  2. [HEALTH] 91 sources
    Melanoma mRNA vaccine reduces recurrence risk by 42%

    A phase 3 trial of a personalized mRNA vaccine developed by Moderna and Merck reduces melanoma recurrence or death risk by 42% when used with pembrolizumab.

Sources

gazetashneta.net · topalbaniaradio.com